Research on malaria and the fight against it. Covers red-blood-cell inflammation, malaria resurgence, drug-resistant parasites, and mosquito-based control.
The malaria parasite affects antigen-presenting dendritic cells in mice, reducing their ability to activate helper T cells and produce cytokines. This impairment leads to the failure of B-cell activation and antibody production, compromising the immune system's response to infection.
Researchers have discovered the structure of Anopheles gambiae's 3-hydroxykynurenine transaminase, a key enzyme in its oxidative defense mechanism. This finding could lead to the development of novel antimalarial agents by inhibiting this enzyme and disrupting the malaria parasite's lifecycle.
A new study by an international team finds that climate change may contribute to malaria's rise, with rising temperatures creating favorable conditions for mosquitoes and pathogen development. The researchers also suggest that other factors such as drug resistance and human migration play roles in the disease's resurgence.
The COMDIS programme aims to improve healthcare quality and coverage for the poor and vulnerable by developing practical and affordable interventions. Effective healthcare systems are crucial in preventing the spread of disease, and the project focuses on addressing bottlenecks and operational constraints to achieve this goal.
A new study shows that seasonal intermittent preventive treatment significantly reduces malaria episodes in children under five, with an 86% decrease observed. The treatment, which involves giving antimalarial medication at defined times without prior testing, has the potential to save millions of lives in Africa.
A new malaria forecasting tool developed by scientists at the University of Liverpool can predict epidemics of malaria up to five months in advance, using climate variability. The model will assist doctors and health care providers in preventing and controlling the disease.
Researchers developed an early-warning system that uses population vulnerability, rainfall, and health surveillance to predict changes in seasonal disease patterns. The system provides health service managers with warnings of changes in epidemic risk five months before the peak malaria season.
A recent study suggests that controlling neglected tropical diseases like leprosy and sleeping sickness may help combat the global fight against HIV/AIDS, tuberculosis, and malaria. Integrating these efforts could provide a cost-effective solution to control or eliminate seven neglected tropical diseases for just $200 million annually.
Research suggests that iron and folic acid supplementation may not benefit all children, particularly those without iron deficiency. However, it may still be beneficial for young children in low-malaria transmission areas due to its role in motor and cognitive development.
Researchers at Howard Hughes Medical Institute have determined how P. falciparum parasites can turn on one cloaking gene and keep dozens of others silent until needed. This discovery reveals the mechanism behind the parasite's survival and has implications for developing new therapies to interfere with its immune evasion strategies.
Researchers have discovered a unique architecture of the Duffy-Binding Like (DBL) domain that allows the malaria parasite to bind to red blood cells. This finding may lead to the development of specific drugs that can target the parasite without affecting healthy blood cells.
Research in three countries found that uncontrolled use of artemisinin led to resistance in Plasmodium falciparum malaria. Mutations in the gene SERCA-type Pftpase6 were associated with this loss of sensitivity. The study highlights the need for increased vigilance and rapid deployment of drug combinations.
A team of researchers has discovered a parasite enzyme, PfSUB2, that sheds sticky surface proteins, allowing the parasite to invade red blood cells. The discovery could lead to the development of new antimalarial drugs that target this enzyme.
A recent clinical trial in Ghana found that IPTi reduced malaria by 25 percent and anemia by 20 percent in children up to 15 months old. Researchers are discussing the results at a symposium on IPTi, which has shown clear potential as a new prevention strategy for fighting malaria in Africa. Similar large-scale implementation studies a...
A new study suggests that malaria may play a key role in mother-to-child transmission of HIV during pregnancy, with high levels of proinflammatory cytokines stimulating HIV replication. Researchers are calling for further investigation and consideration of routine testing and treatment to reduce fetal infection risks.
New study in Cameroon confirms declining effectiveness of malaria drugs like sulfadoxine-pyrimethamine and amodiaquine, highlighting need for alternative treatments. Researchers highlight importance of monitoring resistance and patient adherence to effective treatment regimens.
Researchers have found that two genetic conditions, sickle cell trait and a mild version of thalassemia, offer natural protection against malaria but can be rendered ineffective when occurring together. This study of Kenyan children highlights the complexity of genetic interactions in naturally acquired immunity.
The RTS,S/AS02A vaccine has been shown to reduce the risk of clinical malaria by 30% and severe malaria by 58% in a trial involving over 2000 Mozambican children. The vaccine's efficacy did not wane after 12 months of follow-up, providing sustained protection against clinical malaria for at least 18 months.
A new antimalarial combination, CDA, has shown faster time to reduce parasite levels and greater reductions in parasite viability and reproductive ability compared to current treatments. Phase III trials are planned across sub-Saharan Africa to study its safety and efficacy.
The RTS,S/AS02A vaccine reduced clinical malaria episodes by 35% and severe malaria episodes by 49%. The study followed 14,442 children who received a three-dose regimen of the vaccine in 2003 for an 18-month follow-up period.
A new multilateral initiative aims to develop a sustainable malaria research infrastructure in Africa by supporting competitively awarded grants for centers of excellence. Trained African scientists are crucial in assembling interdisciplinary teams and conducting research projects focused on developing better tools to fight the disease.
Researchers found that household-related factors account for a similar level of variation in susceptibility to malaria as host genetic factors. Children living in high-risk households had twice as many infections per year as those in low-risk households.
Researchers reported that most volunteers developed strong, specific, and long-lasting immune responses to the MSP3 protein after vaccination. The vaccine also demonstrated functional antibody responses that could inhibit malaria parasite growth in laboratory assays.
Children whose mothers had placental malaria were more likely to get sick with the disease themselves. First-time mothers' infants showed a surprising lower risk of developing malaria, regardless of their mother's infection status. These findings suggest that both previous pregnancies and placental malaria impact infant susceptibility.
Researchers discovered that malaria parasite proteins exhibit unique interactions and functions by comparing them to those of yeast, fruit flies, roundworms, and Helicobacter pylori. The study highlights the power of proteomics in understanding complex biological processes and identifying potential targets for new treatments.
Researchers found that a specific gene, SPRN6, is switched on in mosquitoes infected with the malaria parasite, allowing them to defend against it. By knocking out this gene, they observed increased parasite development in some mosquito species and delayed parasite lysis in others.
The Bush Administration proposed purchasing 25% of its food aid abroad to reduce transportation costs, but Senate leaders opposed the move, prioritizing domestic interests over international efforts to combat hunger. The World Food Programme emphasized the need for a concerted global response to address the issue.
A new study finds that a drug combination against AIDS-related infections also prevents malaria in children. The combination, trimethoprim-sulfamethoxazole (TS), was found to be highly effective in preventing malaria, reducing the incidence by 99.5%, and also reduced gastrointestinal illnesses.
A new GM mosquito sexing technique allows for the quick identification of males, paving the way for releasing sterile males to control mosquito populations. This could lead to a significant reduction in malaria cases and population growth.
In KwaZulu-Natal, South Africa, hospital admissions for malaria dropped by 89% after introducing an antimalarial combination called artemether-lumefantrine (AL) and improving mosquito control with DDT. The province also saw a significant decline in outpatient cases and malaria-related deaths.
Researchers used microscopy and fluorescent tags to study malaria parasite release from infected red blood cells. They found that membranes fold into small vesicles allowing parasites to infect neighboring cells through pressure build-up.
The study reveals the malaria parasite's release mechanism from infected red blood cells, contradicting previous theories. The findings provide new insights into the disease and its potential targets for treatment.
The UN's Deputy Secretary General orders delay on measurement of life-saving goals, citing concerns over 'distracting' from desired results. This decision diverts attention from a key problem: concrete trends toward helping people in extreme poverty often lack verification.
Researchers have identified a promising protein, AMA1, as a potential component for a malaria vaccine. The protein is produced in two critical stages of the parasite life cycle and has slight structure variations called polymorphisms that impact its development.
A new trial has found that artesunate is more effective and has fewer side effects than the standard treatment of quinine in treating severe malaria. The study involved over 1,400 patients from four countries and showed a significant reduction in mortality rates with artesunate treatment.
An international team of scientists has discovered the gene PfRh4 that allows the malaria parasite to switch between potential invasion points on red blood cells. The inactivation of this single protein could block multiple entry points currently open to the parasite, paving the way for new anti-malarial vaccine designs.
A randomized controlled trial found that parenteral artesunate reduced mortality from severe malaria by 15% compared to quinine, while also being safer and simpler to administer. The study calls for quality-assured, affordable artesunate to be made widely available in malaria-endemic areas.
Researchers discovered a new compound, LMP-420, that potently reduces activation of endothelial cells and inflammation in cerebral malaria. This finding offers a promising avenue for treating the condition, which has a high fatality rate despite existing treatments.
Researchers develop new method to detect sequestered malaria parasites in red blood cells. The study found that patients with severe malaria have six times higher parasite burden than those without severe symptoms.
A four-year trial in Papua New Guinea is investigating the use of Fansidar as a preventative measure against malaria in children under five and pregnant women. The study suggests that giving just one tablet can reduce the impact of subsequent malaria infections by up to 50%, saving thousands of lives annually.
Researchers found that mosquitoes were significantly more attracted to children with infectious stages of malaria, whereas treatment with antimalarial drugs showed no difference in attractiveness.
Researchers have discovered the molecular mechanism of malaria parasite invasion into red blood cells, revealing a key protein-protein interaction known as the RII handshake. This finding suggests that blocking this interaction could be an effective strategy for preventing and treating malaria.
Researchers found cheaper combination of drugs equally effective as artemisinin-based treatment in preventing recurrent malarial infections. In sites with high transmission rates, the cheaper combination worked better, highlighting cost as a major concern.
Eight Melbourne scientists, including six from WEHI, have been awarded five-year grants to tackle infectious and parasitic diseases like malaria. The $23.3 million international program aims to understand disease mechanisms, identify new drug targets, and develop vaccines.
Researchers are developing genetically altered malaria parasites to stimulate immunity against the disease. The goal is to boost the immune system in a similar way to how the altered polio bacteria triggers immunity against polio.
Menzies Research Institute director Professor Foote awarded $17.5 million US grant to expand genetic research program on malaria. He will investigate how humans' immune systems fight malaria by infecting lab mice with rare genetic mutations.
The Howard Hughes Medical Institute (HHMI) has selected 42 biomedical scientists from around the world to receive international research grants. These awardees will contribute to advancing global health and medical innovation through their research projects, with a focus on infectious diseases, parasitology, and immunology.
Researchers at Vanderbilt University aim to develop powerful chemical repellents and attractants to interfere with malaria mosquitoes' ability to find human targets. The project uses genetic engineering, molecular biology, and field-based studies to establish an effective strategy for reducing malaria spread.
A Yale University research project aims to reduce malaria transmission by identifying effective odor cues that attract or repel mosquitoes. The team will test these odors in simulated natural situations and eventually distribute them to African villages for practical tests.
Researchers found that abnormal distribution of PfEMP-1 protein on red blood cells containing hemoglobin C impairs malaria parasites' ability to cause disease symptoms. This may explain why individuals with at least one gene for hemoglobin C are less prone to severe malaria.
Researchers have found that carrying the sickle cell gene provides partial protection against malaria, increasing to 60% in childhood before declining. The study suggests an immune component to this protection and may offer insights into developing an effective vaccine.
Researchers developed disease models using yeast to test resistance to atovaquone and created a practical tool to design new anti-malarial drugs. This study provides the first quantitative explanation for malaria's drug resistance, enabling the development of new treatments within 3-5 years.
A randomized trial in Uganda found a six-dose regimen of co-artemether significantly reduced gametocyte levels and mosquito infectivity. However, limitations include patient compliance and absorption issues.
A new study found that administering anti-malarial drugs to infants just three times can reduce the incidence of malaria by 59% in the first year of life. The treatment, known as intermittent preventative malarial treatment (IPT), was also shown to provide long-term protection against malaria episodes in children up to two years old.
A malaria vaccine, RTS, S/AS02, has shown substantial protection in trials, with 30% and 58% effectiveness rates. However, an efficacious vaccine is not yet available for widespread use due to funding and organizational challenges. Experts predict a decade-long timeline for the development of a viable vaccine.
A recent study has found that a combination of artemether-lumefantrine to be highly effective in treating malaria in children aged 4-59 months. The treatment showed an impressive success rate of over 96% in a Tanzanian trial, paving the way for its potential use as a substitute for failing therapies in African countries.
The Roll Back Malaria partnership, which includes WHO, UNICEF, and the World Bank, has failed to achieve its aims of reducing malaria mortality. Despite a seven-year initiative, malaria rates have increased, making it unlikely that the 2010 target to halve deaths will be met.
Pneumonia, diarrhea, and undernutrition are major contributors to child deaths worldwide. The new estimates also show that nearly half of all child deaths occur within the first 28 days of life, primarily due to preterm delivery, sepsis, or pneumonia.
In West Papua, patients often initially choose indigenous treatments for illnesses, but switch to biomedical options if they don't work. After initial failure, individuals focus on finding the cause of their illness, attributing it to factors like ancestral spirits, magic, or biological responses.
A study found that US Army personnel deployed to eastern Afghanistan between June and September 2002 had a significant risk of malaria infection upon return. The researchers identified 38 patients infected with malaria, resulting in an attack rate of 52.4 cases per 1,000 soldiers.